<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061524</url>
  </required_header>
  <id_info>
    <org_study_id>YH35324-101</org_study_id>
    <nct_id>NCT05061524</nct_id>
  </id_info>
  <brief_title>A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases</brief_title>
  <official_title>A First-in-Human, Randomized, Double-Blind, Placebo/Active Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, PK, and PD following&#xD;
      subcutaneous injections of YH35324 in atopic healthy subjects or adult subjects with mild&#xD;
      allergic diseases. Eligible subjects will be randomized to the YH35324 group, the placebo&#xD;
      group, or the omalizumab group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      YH35324 is a drug under development as a novel therapeutic agent for various IgE-mediated&#xD;
      allergic diseases. Since YH35324 has a high binding affinity to human IgE, it prevents serum&#xD;
      IgE from binding to receptors on mast cells and basophil, thereby inhibiting histamine&#xD;
      release caused by degranulation when exposed to allergens Based on its non-clinical study&#xD;
      results, this study aims to evaluate the safety, tolerability, PK, and PD following&#xD;
      subcutaneous injections of YH35324 in atopic healthy subjects or subjects with mild allergic&#xD;
      diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 26, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability following single administration of YH35324</measure>
    <time_frame>Occurrence and severity of adverse events will be observed for 113 days after administration</time_frame>
    <description>Occurrence and severity of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PK of YH35324</measure>
    <time_frame>Serum concentrations of YH35324 will be observed for 113 days after administration</time_frame>
    <description>Serum concentrations of YH35324</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PD of YH35324</measure>
    <time_frame>Change in serum Free/Total IgE level will be observed for 113 days after administration</time_frame>
    <description>Change in serum Free/Total IgE level</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To explore the PD of YH35324</measure>
    <time_frame>Changes in FcεRI expression will be observed for 57days after administration</time_frame>
    <description>Changes in FcεRI expression</description>
  </other_outcome>
  <other_outcome>
    <measure>To explore inhibition on allergens (allergy antigens) of YH35324</measure>
    <time_frame>Changes in allergen-induced skin prick wheal response will be observed for 57 days after administration</time_frame>
    <description>Changes in allergen-induced skin prick wheal response</description>
  </other_outcome>
  <other_outcome>
    <measure>To explore the immunogenicity of YH35324</measure>
    <time_frame>Incidence of serum Anti-YH35324 antibodies will be observed for 113 Days after administration</time_frame>
    <description>Incidence of serum Anti-YH35324 antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>To explore inhibition on allergens (allergy antigens) of YH35324</measure>
    <time_frame>Changes in allergen-induced serum allergen specific IgE level will be observed for 57 days after administration</time_frame>
    <description>Changes in serum allergen specific IgE level</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Atopic Healthy Subjects</condition>
  <condition>Adult Subjects With Mild Allergic Diseases</condition>
  <arm_group>
    <arm_group_label>YH35324</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: A single dose of the YH35324 will be administered subcutaneously in 5 dose groups (0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses&#xD;
Part B: A single dose of the YH35324 will be administered subcutaneously. The dose of YH35324 will be determined after the safety, tolerability, PK, and PD data in Part A are reviewed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: A single dose of the Placebo will be administered subcutaneously in 5 Cohorts(Dose groups=0.3, 1, 3, 6, and 9 mg/kg), and a dose will be escalated in a stepwise manner from low to high doses&#xD;
Part B: Placebo is not administered in Part B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xolair® for injection (Omalizumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part A: A single fixed dose of the Omalizumab 300mg will be administered subcutaneously in 4 Cohorts(Dose groups of YH35324=1, 3, 6, and 9 mg/kg)&#xD;
Part B: A single dose of the Omalizumab 300mg will be administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH35324</intervention_name>
    <description>Subcutaneous injection of YH35324</description>
    <arm_group_label>YH35324</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of None of active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Subcutaneous injection of Omalizumab</description>
    <arm_group_label>Xolair® for injection (Omalizumab)</arm_group_label>
    <other_name>Xolair® for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19~55 years old, Atopic Healthy Subjects or Subjects With Mild Allergic Diseases&#xD;
&#xD;
          -  Serum total IgE level of 30 to 700 IU/mL or &gt; 700 IU/mL&#xD;
&#xD;
          -  Signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hyperimmunoglobulin E syndrome or malignancy&#xD;
&#xD;
          -  Positive drug screen result&#xD;
&#xD;
          -  AST or ALT &gt; 1.5 * Upper normal range&#xD;
&#xD;
          -  eGFR &lt; 60mL/min/1.73m2&#xD;
&#xD;
          -  Allergy immunotherapy initiated or Administration of a live vaccine within 3 months&#xD;
             prior to randomization&#xD;
&#xD;
          -  History of participation in another clinical trial within 6 months prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eunji Song</last_name>
    <phone>02-828-0736</phone>
    <email>ejsong@yuhan.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Pungnap-tong</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Sinchon-dong</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gumi</city>
        <state>Sungnamsi</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to yhcho@yuhan.co.kr.&#xD;
A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Beginning 1 year and ending 5 years after all trial endpoints were assessed</ipd_time_frame>
    <ipd_access_criteria>Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to yhcho@yuhan.co.kr.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

